Analyst Price Targets — INDV
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 20, 2026 2:08 pm | — | Northland Securities | $50.00 | $33.05 | TheFly | Indivior price target raised to $50 from $40 at Northland |
| January 12, 2026 11:04 am | — | H.C. Wainwright | $48.00 | $35.44 | TheFly | Indivior price target raised to $48 from $35 at H.C. Wainwright |
| December 3, 2025 11:32 am | — | Morgan Stanley | $36.00 | $34.00 | TheFly | Indivior price target raised to $36 from $28 at Morgan Stanley |
| October 31, 2025 1:25 pm | — | Craig-Hallum | $41.00 | $29.27 | TheFly | Indivior price target raised to $41 from $34 at Craig-Hallum |
| October 31, 2025 1:16 pm | — | Northland Securities | $40.00 | $29.67 | TheFly | Indivior price target raised to $40 from $30 at Northland |
| October 30, 2025 4:26 pm | Brandon Folkes | H.C. Wainwright | $35.00 | $29.14 | TheFly | Indivior price target raised to $35 from $28 at H.C. Wainwright |
| August 27, 2025 1:06 pm | Chase Knickerbocker | Craig-Hallum | $34.00 | $24.51 | TheFly | Indivior price target raised to $34 from $27 at Craig-Hallum |
| March 6, 2025 11:46 am | — | Piper Sandler | $13.00 | $9.89 | TheFly | Indivior price target lowered to $13 from $16 at Piper Sandler |
| October 11, 2024 7:58 am | David Amsellem | Piper Sandler | $15.00 | $7.61 | StreetInsider | Piper Sandler Reiterates Overweight Rating on Indivior (INDV) |
| September 23, 2024 9:33 am | Chase Knickerbocker | Craig-Hallum | $20.00 | $9.16 | StreetInsider | Indivior (INDV) PT Lowered to $20 at Craig-Hallum |
Latest News for INDV
Indivior Pharmaceuticals, Inc. (INDV) Q4 2025 Earnings Call Transcript
RICHMOND, Va., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today reported its financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.
RICHMOND, Va., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will participate in the following upcoming investor conferences: Barclays 28th Annual Global Healthcare Conference – Miami, FL Joe Ciaffoni, Chief Executive Officer, will host 1x1 / group meetings on Tuesday, March 10th.
Indivior PLC (NASDAQ: INDV - Get Free Report) has earned a consensus rating of "Moderate Buy" from the seven analysts that are covering the company, Marketbeat reports. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1-year price objective among brokers that
RICHMOND, Va., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its fourth quarter and full-year 2025 financial results on Thursday, February 26, 2026, at 7:00 a.m. U.S. EST. Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members of Indivior's leadership team will host a presentation via live webcast…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for INDV.
U.S. House Trading
No House trades found for INDV.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.